Important note: Information in this article was accurate in August 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 8, August 2005
Simon Collins, HIV i-Base
In the last issue of HTB we reported that six Indian manufactured generic ARVs received FDA tentative approval.
Further approvals have since been granted for a generic combination drug product consisting of lamivudine and zidovudine, manufactured by Aurobindo Pharma (on 7 July 2005); and zidovudine tablets manufactured by Ranbaxy Laboratories (on 13 July).
Tentative approval means that although existing patents and/or exclusivity prevent marketing of this product in the United States, it meets the quality, safety and efficacy standards for U.S. marketing. This makes these generic products eligible for purchase and use outside the United States under the President’s Emergency Plan for AIDS Relief (PEPFAR).
When this fast-track approval for generic antiretroviral drugs was first announced there was wide skepticism that may have been a stalling mechanism in order to retain preferential purchase but the US government for US-manufactured brand ARV. While FDA approval shouldn’t be necessary in addition to the WHO pre-qualification process, this rapid series of tentative approvals should at least end earlier attempts by some organisations to discredit the quality of the generic ARVs produced by the largest major Indian generic companies.
An archive of past list serve announcements is available on the FDA web site at:
Food and Drug Administration list serve archive
050810
IB050608-06
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
